Kingsway Financial Services Enhances Diagnostics with CIGA Healthcare Acquisition
- Kingsway Pharmaceuticals acquires a minority stake in CIGA Healthcare to enhance its diagnostics offerings and supply chain reliability.
- The partnership aims to provide accessible home diagnostic products, supporting informed health decisions for consumers.
- Kingsway celebrates retail wins in the private label market, aligning with its innovative strategy and commitment to consumer health.
Kingsway Pharmaceuticals Strengthens Diagnostic Offerings Through Strategic Acquisition
Kingsway Pharmaceuticals, a prominent U.S. consumer healthcare company, solidifies its position in the diagnostics sector by acquiring a minority stake in CIGA Healthcare. This innovative company specializes in rapid tests and home diagnostic technologies, distributing its products to over 70 countries worldwide. The partnership, announced on November 17, 2025, is aimed at enhancing Kingsway's supply chain reliability and expediting the rollout of both branded and private label diagnostic products across major U.S. retailers. By leveraging CIGA Healthcare’s established portfolio, which includes a diverse range of diagnostic products, Kingsway seeks to bolster consumer confidence in health management through accessible testing solutions.
Benjamin Blessing, the Chief Operating Officer of Kingsway Pharmaceuticals, highlights the collaboration’s significance in providing families with essential health insights. He emphasizes that this strategic partnership will create a more stable supply path for diagnostics in the U.S., allowing Kingsway to broaden its innovative offerings to consumers. The focus on reliable supply chains is critical, especially in a post-pandemic landscape where home diagnostics have become increasingly vital. This partnership empowers Kingsway to deliver timely and accurate health information, facilitating informed decisions among consumers regarding their health and wellness.
CIGA Healthcare's extensive product range, which includes tests for pregnancy and fertility, women's health, UTI screening, menopause, respiratory and allergy diagnostics, as well as glucose monitoring systems, positions it as a key player in the healthcare sector. Irwin Armstrong, CEO of CIGA Healthcare, expresses enthusiasm for the collaboration, noting that Kingsway's strong retail relationships and brand-building expertise will enhance the accessibility of their diagnostic solutions. The synergy between the two companies aims to ensure scalable manufacturing and rapid market entry for these crucial products, ultimately expanding access to testing across various categories and markets.
In addition to the strategic partnership with CIGA Healthcare, Kingsway Pharmaceuticals has made significant strides in the private label market. The company recently celebrated two substantial retailer wins in 2025, illustrating its commitment to innovation and market expansion. This development aligns with the strategic goals of both Kingsway and CIGA Healthcare, as they strive to empower households with the necessary tools for informed health decisions.
The acquisition underscores Kingsway’s dedication to enhancing consumer health through reliable and innovative diagnostic solutions, ultimately contributing to a more health-conscious society.